Terazosin
Product Images NDC 66267-325

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 66267-325). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (66267 325 30 J32)

Label for Terazosin 5 mg capsules, packaged by NuCare Pharmaceuticals, Inc. The label indicates a bottle quantity of 30 capsules. It notes that each capsule contains Terazosin Hydrochloride equivalent to 5 mg of Terazosin, USP. The capsules are described as oblong, orange, opaque, with "TL 385" printed on the body and cap. Additional label information includes warnings to keep out of reach of children, storage instructions at 68-77°F, and prescription-only status.*

FDA Label Image

Terazosin Hydrochloride Chemical Structure (Terazosin Hydrochloride Capsules 1)

Chemical structure of the active ingredient Terazosin hydrochloride, showing its molecular arrangement with aromatic rings, nitrogen atoms, and functional groups as part of the molecule.*

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

This figure contains two line graphs comparing Terazosin and placebo groups over a 3-month period. The left graph shows the mean change in total symptom score from baseline, with Terazosin showing a greater decrease compared to placebo. The right graph depicts mean increase in peak flow rate (mL/sec) from baseline, where Terazosin results in a higher increase relative to placebo. Sample sizes are noted for each group at 3 months.*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

A line chart depicting mean change from baseline over time in months, from 0 to 30. The vertical axis shows change values ranging approximately from 0 to -7. Data points with error bars indicate a decreasing trend that stabilizes after initial months, with asterisks marking certain points along the curve.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

A line graph illustrating the mean change from baseline in mL per second over a 30-month period. The x-axis represents time in months from 0 to 30, and the y-axis shows mean change from baseline values ranging from 0 to 4.5. Data points include error bars, and several points are marked with asterisks indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.